Lipocine (NASDAQ:LPCN) Stock Crosses Below 200-Day Moving Average – Here’s Why

Lipocine Inc. (NASDAQ:LPCN) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $5.17 and traded as low as $4.96. Lipocine shares last traded at $5.23, with a volume of 24,592 shares.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. StockNews.com assumed coverage on Lipocine in a report on Thursday. They set a “hold” rating for the company. Alliance Global Partners started coverage on shares of Lipocine in a report on Tuesday, September 24th. They set a “buy” rating and a $10.00 target price on the stock.

Lipocine Stock Down 1.1 %

The firm has a market capitalization of $27.97 million, a PE ratio of -6.88 and a beta of 1.23. The company has a 50-day moving average of $5.03 and a 200 day moving average of $5.17.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter. As a group, equities analysts anticipate that Lipocine Inc. will post -0.78 EPS for the current fiscal year.

Institutional Trading of Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP bought a new stake in Lipocine Inc. (NASDAQ:LPCN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine as of its most recent SEC filing. Hedge funds and other institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.